Methods of treating inflammatory colon diseases
A method of treating ulcerative colitis or Crohn's disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells from a placenta or adipose tissue, thereby treating the ulcerative colitis or Crohn's disease.
1. A method of treating inflammation of intestinal tissue in conditions of ulcerative colitis or Crohn's disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of adherent, non-autologous cells derived from placenta, thereby treating the inflammation of intestinal tissue in conditions of ulcerative colitis or Crohn's disease, wherein said adherent, non-autologous cells do not exhibit osteogenic differentiation as assessed by Alizarin Red staining, when subjected to conditions that induce bone marrow cells to undergo osteogenic differentiation.
2. The method of claim 1 , wherein said adherent cells express one or more of CD73, CD90, CD29, or CD105.
3. The method of claim 1 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, or CD79.
4. The method of claim 1 , wherein said adherent cells suppress an immune reaction by suppressing T cell activity.
5. The method of claim 1 , wherein said adherent cells are obtained from a three-dimensional (3D) culture.
6. The method wherein said three-dimensional (3D) culture comprises a 3D bioreactor.
7. The method wherein culturing of said adherent cells in said 3D culture comprises perfusion of the adherent cells with a continuous flow of a culture medium.
8. The method wherein culturing of said adherent cells occurs for at least 3 days.
9. The method of claim 1 , wherein said adherent cells comprise cells cultured from the placenta under 2 dimensional (2D) culturing conditions.
10. The method wherein at least 12% of said adherent cells are at a S and/or G2/M proliferative phase.
11. The method of claim 1 , wherein said adherent cells are less committed to an adipogenic lineage as compared to adherent cells from bone marrow grown and allowed to differentiate under the same conditions.
12. The method of claim 1 , further comprising co-administering an immunosuppressant agent or an anti-inflammatory agent.
13. The method of claim 1 , wherein the adherent, non-autologous cells are administered via one of an intravenous, intramuscular, or intraperitoneal injection.
14. The method of claim 1 , wherein said adherent, non-autologous cells do not express CD34.